Financial Advocates Investment Management Acquires 10,016 Shares of Teladoc Health, Inc. (NYSE:TDOC)

Financial Advocates Investment Management grew its holdings in shares of Teladoc Health, Inc. (NYSE:TDOCGet Rating) by 67.2% in the 2nd quarter, according to its most recent disclosure with the SEC. The fund owned 24,914 shares of the health services provider’s stock after acquiring an additional 10,016 shares during the period. Financial Advocates Investment Management’s holdings in Teladoc Health were worth $827,000 as of its most recent SEC filing.

Several other large investors have also recently modified their holdings of the business. McCarthy Asset Management Inc. bought a new position in Teladoc Health during the first quarter worth $25,000. DB Wealth Management Group LLC bought a new position in Teladoc Health during the first quarter worth $25,000. Oliver Lagore Vanvalin Investment Group bought a new position in Teladoc Health during the first quarter worth $27,000. SeaCrest Wealth Management LLC bought a new position in Teladoc Health during the second quarter worth $28,000. Finally, Bank Julius Baer & Co. Ltd Zurich raised its stake in Teladoc Health by 962.0% during the second quarter. Bank Julius Baer & Co. Ltd Zurich now owns 1,062 shares of the health services provider’s stock worth $35,000 after buying an additional 962 shares during the last quarter. Institutional investors own 92.46% of the company’s stock.

Insiders Place Their Bets

In other Teladoc Health news, SVP Daniel Trencher sold 1,000 shares of Teladoc Health stock in a transaction dated Monday, September 19th. The shares were sold at an average price of $30.18, for a total value of $30,180.00. Following the sale, the senior vice president now owns 25,408 shares of the company’s stock, valued at $766,813.44. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In other news, SVP Daniel Trencher sold 1,000 shares of the business’s stock in a transaction that occurred on Monday, September 19th. The shares were sold at an average price of $30.18, for a total value of $30,180.00. Following the sale, the senior vice president now owns 25,408 shares of the company’s stock, valued at $766,813.44. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, insider Arnnon Geshuri sold 4,098 shares of the business’s stock in a transaction that occurred on Friday, August 26th. The shares were sold at an average price of $34.27, for a total transaction of $140,438.46. Following the completion of the sale, the insider now directly owns 76,182 shares in the company, valued at approximately $2,610,757.14. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 6,845 shares of company stock valued at $216,314. Company insiders own 1.55% of the company’s stock.

Teladoc Health Stock Performance

Shares of TDOC stock opened at $28.57 on Thursday. The company has a quick ratio of 2.99, a current ratio of 3.13 and a debt-to-equity ratio of 0.25. Teladoc Health, Inc. has a 52 week low of $23.08 and a 52 week high of $119.98. The firm’s 50-day simple moving average is $27.57 and its two-hundred day simple moving average is $32.37.

Teladoc Health (NYSE:TDOCGet Rating) last announced its quarterly earnings data on Wednesday, October 26th. The health services provider reported ($0.45) EPS for the quarter, topping the consensus estimate of ($0.59) by $0.14. The business had revenue of $611.40 million for the quarter, compared to analyst estimates of $609.45 million. Teladoc Health had a negative net margin of 424.40% and a negative return on equity of 2.47%. On average, equities research analysts forecast that Teladoc Health, Inc. will post -1.4 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on the stock. Cowen cut shares of Teladoc Health from an “outperform” rating to a “market perform” rating and reduced their price target for the stock from $58.00 to $34.00 in a report on Tuesday, August 2nd. Oppenheimer reduced their price target on shares of Teladoc Health from $55.00 to $45.00 in a report on Thursday, October 27th. Cowen reduced their price target on shares of Teladoc Health to $30.00 in a report on Thursday, October 27th. Barclays reduced their price target on shares of Teladoc Health from $33.00 to $32.00 and set an “equal weight” rating for the company in a report on Thursday, October 27th. Finally, DA Davidson reduced their price target on shares of Teladoc Health from $45.00 to $40.00 and set a “buy” rating for the company in a report on Tuesday, October 25th. One analyst has rated the stock with a sell rating, twenty-two have issued a hold rating and four have assigned a buy rating to the stock. According to MarketBeat, Teladoc Health presently has a consensus rating of “Hold” and an average target price of $48.32.

Teladoc Health Company Profile

(Get Rating)

Teladoc Health, Inc engages in the provision of telehealthcare services using a technology platform via mobile devices, the Internet, video and phone. Its portfolio of services and solutions covers medical subspecialties from non-urgent, episodic needs like flu and upper respiratory infections, to chronic, complicated medical conditions like cancer and congestive heart failure.

See Also

Want to see what other hedge funds are holding TDOC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Teladoc Health, Inc. (NYSE:TDOCGet Rating).

Institutional Ownership by Quarter for Teladoc Health (NYSE:TDOC)

Receive News & Ratings for Teladoc Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teladoc Health and related companies with MarketBeat.com's FREE daily email newsletter.